VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

EssilorLuxottica vs Roche Holding AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

EssilorLuxottica

EL · Euronext Paris

Market cap (USD)$110.3B
Gross margin (TTM)61.5%
Operating margin (TTM)12.4%
Net margin (TTM)8.5%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryFR
Data as of2026-01-11
Moat score
69/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into EssilorLuxottica's moat claims, evidence, and risks.

View EL analysis

Roche Holding AG

ROG · SIX Swiss Exchange

Market cap (USD)$292.8B
Gross margin (TTM)73.4%
Operating margin (TTM)30.8%
Net margin (TTM)17.1%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryCH
Data as of2025-12-28
Moat score
68/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Roche Holding AG's moat claims, evidence, and risks.

View ROG analysis

Comparison highlights

  • Moat score gap: EssilorLuxottica leads (69 / 100 vs 68 / 100 for Roche Holding AG).
  • Segment focus: EssilorLuxottica has 2 segments (52.7% in Direct to Consumer); Roche Holding AG has 2 segments (76.3% in Pharmaceuticals).
  • Moat breadth: EssilorLuxottica has 5 moat types across 3 domains; Roche Holding AG has 5 across 3.

Primary market context

EssilorLuxottica

Direct to Consumer

Market

Optical retail and e-commerce (prescription eyewear and sunglasses)

Geography

Global

Customer

Consumers (end-users)

Role

Omnichannel retailer + vertically integrated manufacturer/brand owner

Revenue share

52.7%

Roche Holding AG

Pharmaceuticals

Market

Innovative (branded) prescription pharmaceuticals

Geography

Global

Customer

Healthcare providers and systems (hospitals/clinics), payers/governments, and patients

Role

Innovator pharmaceutical developer, manufacturer and marketer

Revenue share

76.3%

Side-by-side metrics

EssilorLuxottica
Roche Holding AG
Ticker / Exchange
EL - Euronext Paris
ROG - SIX Swiss Exchange
Market cap (USD)
$110.3B
$292.8B
Gross margin (TTM)
61.5%
73.4%
Operating margin (TTM)
12.4%
30.8%
Net margin (TTM)
8.5%
17.1%
Sector
Healthcare
Healthcare
Industry
Medical - Instruments & Supplies
Drug Manufacturers - General
HQ country
FR
CH
Primary segment
Direct to Consumer
Pharmaceuticals
Market structure
Competitive
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
69 / 100
68 / 100
Moat domains
Legal, Supply, Demand
Legal, Supply, Demand
Last update
2026-01-11
2025-12-28

Moat coverage

Shared moat types

IP Choke Point

EssilorLuxottica strengths

Distribution ControlScale Economies Unit CostBrand TrustContractual Exclusivity

Roche Holding AG strengths

Capex Knowhow ScaleInstalled Base ConsumablesData Workflow LockinRegulated Standards Pipe

Segment mix

EssilorLuxottica segments

Full profile >

Professional Solutions

Oligopoly

47.3%

Direct to Consumer

Competitive

52.7%

Roche Holding AG segments

Full profile >

Pharmaceuticals

Competitive

76.3%

Diagnostics

Oligopoly

23.7%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.